Literature DB >> 23554269

In-depth analysis of hyaline fibromatosis syndrome frameshift mutations at the same site reveal the necessity of personalized therapy.

Shixu E Yan1, Thomas Lemmin, Suzanne Salvi, Ekkehart Lausch, Andrea Superti-Furga, Dariusz Rokicki, Matteo Dal Peraro, F Gisou van der Goot.   

Abstract

Hyaline fibromatosis syndrome is an autosomal recessive disease caused by mutations in ANTXR2, a gene involved in extracellular matrix homeostasis. Sixty percent of patients carry frameshift mutations at a mutational hotspot in exon 13. We show in patient cells that these mutations lead to low ANTXR2 mRNA and undetectable protein levels. Ectopic expression of the proteins encoded by the mutated genes reveals that a two base insertion leads to the synthesis of a protein that is rapidly targeted to the ER-associated degradation pathway due to the modified structure of the cytosolic tail, which instead of being hydrophilic and highly disordered as in wild type ANTXR2, is folded and exposes hydrophobic patches. In contrast, one base insertion leads to a truncated protein that properly localizes to the plasma membrane and retains partial function. We next show that targeting the nonsense mediated mRNA decay pathway in patient cells leads to a rescue of ANTXR2 protein in patients carrying one base insertion but not in those carrying two base insertions. This study highlights the importance of in-depth analysis of the molecular consequences of specific patient mutations, which even when they occur at the same site can have drastically different consequences.
© 2013 WILEY PERIODICALS, INC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23554269     DOI: 10.1002/humu.22324

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Infantile Systemic Hyalinosis: Novel Founder Mutation in the Initiation Codon among "Malis (Farmers)" in Jodhpur.

Authors:  Jai Prakash Soni; Ratna D Puri; Kapil Jetha; G S L Bhavani; Monika Chaudhary; Sudha Kohli; I C Verma
Journal:  Indian J Pediatr       Date:  2016-10-18       Impact factor: 1.967

2.  Hyaline fibromatosis syndrome with mutation c.1074delT of the CMG2 gene: a case report.

Authors:  Imane Cherkaoui Jaouad; Soukaina Guaoua; Aicha Hajjioui; Abdelaziz Sefiani
Journal:  J Med Case Rep       Date:  2014-09-03

3.  Diagnosis implications of the whole genome sequencing in a large Lebanese family with hyaline fibromatosis syndrome.

Authors:  Zahraa Haidar; Ramzi Temanni; Eliane Chouery; Puthen Jithesh; Wei Liu; Rashid Al-Ali; Ena Wang; Francesco M Marincola; Nadine Jalkh; Soha Haddad; Wassim Haidar; Lotfi Chouchane; André Mégarbané
Journal:  BMC Genet       Date:  2017-01-19       Impact factor: 2.797

4.  The genetic basis of hyaline fibromatosis syndrome in patients from a consanguineous background: a case series.

Authors:  Leila Youssefian; Hassan Vahidnezhad; Andrew Touati; Vahid Ziaee; Amir Hossein Saeidian; Sara Pajouhanfar; Sirous Zeinali; Jouni Uitto
Journal:  BMC Med Genet       Date:  2018-05-25       Impact factor: 2.103

5.  Protein-losing enteropathy and joint contractures caused by a novel homozygous ANTXR2 mutation.

Authors:  Edith Schussler; Rita V Linkner; Jacob Levitt; Lakshmi Mehta; John A Martignetti; Kimihiko Oishi
Journal:  Adv Genomics Genet       Date:  2018-06-27

6.  Clinical aspects of Hyaline Fibromatosis Syndrome and identification of a novel mutation.

Authors:  Bettina Härter; Francesco Benedicenti; Daniela Karall; Ekkehard Lausch; Gisela Schweigmann; Franco Stanzial; Andrea Superti-Furga; Sabine Scholl-Bürgi
Journal:  Mol Genet Genomic Med       Date:  2020-03-20       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.